SIRT3, a metabolic target linked to ataxia-telangiectasia mutated (ATM) gene deficiency in diffuse large B-cell lymphoma.

SIRT3, a metabolic target linked to ataxia-telangiectasia mutated (ATM) gene deficiency in diffuse large B-cell lymphoma.
复制标题

DOI:
10.1038/s41598-020-78193-6
复制
发表时间:
2020-12-03
期刊:
影响因子:
4.6
通讯作者:
Gartenhaus RB
Gartenhaus RB
中科院分区:
综合性期刊3区
文献类型:
--
作者:
Bhalla K;Jaber S;Reagan K;Hamburg A;Underwood KF;Jhajharia A;Singh M;Bhandary B;Bhat S;Nanaji NM;Hisa R;McCracken C;Creasy HH;Lapidus RG;Kingsbury T;Mayer D;Polster B;Gartenhaus RB

文献摘要

参考文献

被引文献

相似文献

共济失调毛细血管扩张突变 (ATM) 基因失活会导致患癌症的风险增加。我们发现,与表达野生型 (WT)-ATM 的 DLBCL 细胞相比,弥漫性大 B 细胞淋巴瘤 (DLBCL) 中的 ATM 缺陷显着诱导线粒体脱乙酰酶 Sirtuin-3 (SIRT3) 活性,破坏线粒体结构,减少线粒体呼吸,并损害 TCA 通量。与 WT-ATM DLBCL 细胞相比,这对应于 ATM 缺陷背景中谷氨酸受体和谷氨酰胺途径的富集。与放射敏感的非癌性 A-T 细胞相比,ATM−/− DLBCL 细胞的凋亡减少。使用 SIRT3 表达的获得和缺失的体内研究表明,与野生型 ATM 对照异种移植物相比,SIRT3 促进 ATM CRISPR 敲除 DLBCL 异种移植物的生长。重要的是,DLBCL 患者样本的筛查将 SIRT3 确定为假定的治疗靶点,并验证了 ATM 和 SIRT3 表达之间的负相关关系。我们的数据预测 SIRT3 是 ATM 无效表型 DLBCL 患者的重要治疗靶点。
Inactivation of Ataxia-telangiectasia mutated (ATM) gene results in an increased risk to develop cancer. We show that ATM deficiency in diffuse large B-cell lymphoma (DLBCL) significantly induce mitochondrial deacetylase sirtuin-3 (SIRT3) activity, disrupted mitochondrial structure, decreased mitochondrial respiration, and compromised TCA flux compared with DLBCL cells expressing wild type (WT)-ATM. This corresponded to enrichment of glutamate receptor and glutamine pathways in ATM deficient background compared to WT-ATM DLBCL cells. ATM−/− DLBCL cells have decreased apoptosis in contrast to radiosensitive non-cancerous A-T cells. In vivo studies using gain and loss of SIRT3 expression showed that SIRT3 promotes growth of ATM CRISPR knockout DLBCL xenografts compared to wild-type ATM control xenografts. Importantly, screening of DLBCL patient samples identified SIRT3 as a putative therapeutic target, and validated an inverse relationship between ATM and SIRT3 expression. Our data predicts SIRT3 as an important therapeutic target for DLBCL patients with ATM null phenotype.
肿瘤抑制因子 SIRT3 脱乙酰并激活锰超氧化物歧化酶清除 ROS
DOI: 10.1038/embor.2011.65
发表时间: 2011-06
期刊: EMBO REPORTS
影响因子: 7.7
作者:
Chen, Yaohui;Zhang, Jinye;Lin, Yan;Lei, Qunying;Guan, Kun-Liang;Zhao, Shimin;Xiong, Yue
通讯作者: Xiong, Yue
DOI: 10.1242/dev.177022
发表时间: 2020-01-01
期刊: DEVELOPMENT
影响因子: 4.6
作者:
Creed,T. Michael;Baldeosingh,Rajkumar;Kingsbury,Tami J.
通讯作者: Kingsbury,Tami J.
DOI: 10.1093/hmg/ddv342
发表时间: 2015-11-15
影响因子: 3.5
作者:
Campbell, Andrew;Krupp, Brittany;Mayer-Proeschel, Margot
通讯作者: Mayer-Proeschel, Margot
NAD(+)补给可以通过线粒体和DNA修复来改善telangiectasia模型中的寿命和健康状态。
DOI: 10.1016/j.cmet.2016.09.004
发表时间: 2016-10-11
期刊: Cell metabolism
影响因子: 29
作者:
Fang EF;Kassahun H;Croteau DL;Scheibye-Knudsen M;Marosi K;Lu H;Shamanna RA;Kalyanasundaram S;Bollineni RC;Wilson MA;Iser WB;Wollman BN;Morevati M;Li J;Kerr JS;Lu Q;Waltz TB;Tian J;Sinclair DA;Mattson MP;Nilsen H;Bohr VA
通讯作者: Bohr VA
DOI: 10.1073/pnas.0708043104
发表时间: 2007-10-16
影响因子: 11.1
作者:
Feng, Zhaohui;Hu, Wenwei;Levine, Arnold J.
通讯作者: Levine, Arnold J.